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Pigment gene small nucleotide polymorphisms 
and nonmelanoma skin cancer
This systematic review by Binstock et al. starts by stating that non-
melanoma skin cancer (NMSC) is the most common cancer in 
the U.S.A., and then highlights the fact that the associations of 
single-nucleotide polymorphisms (SNPs) of pigmentation path-
way genes with NMSC are not well characterized. However, 
there are several epidemiological studies that have tested these 
relationships. Binstock et al. undertook a systematic review of 
these published studies and concluded that the summarized 
data supported the concept that specific SNPs in the pigmenta-
tion pathway are of importance for the pathogenesis of NMSC. 
They report that the SNPs with the most promising evidence were 
MC1R rs1805007(T) (Arg151Cys) and rs1805008(T) (Arg160Trp), 
and ASIP AH haplotype [rs4911414(T) and rs1015362(G)]. They 
conclude that additional research has the potential for the transla-
tion of future findings to the clinic in the form of SNP screenings, 
where patients at high risk for NMSC can be identified beyond 
their phenotype by genotypically screening for predisposing 
SNPs. Br J Dermatol 2014; 171: 713–721.
Vitiligo and autoantibodies against thyroid 
hormones
In this study, Colucci et al. commence by explaining that autoan-
tibodies against thyroid hormones (THAbs) directed towards triio-
dothyronine (T3-Ab) and/or thyroxine (T4-Ab) are very rare in the 
general population and are increased in some nonthyroidal auto-
immune diseases, where they seem to predict autoimmune thyroid 
disorders. They go on to explain that their presence in patients with 
vitiligo has not, until now, been evaluated. Their aim was to assess 
the prevalence of THAbs in a group of patients with vitiligo and 
to correlate their presence with clinical and historical parameters. 
Seventy-nine patients with nonsegmental vitiligo and 100 con-
trols were examined. Clinical characteristics of vitiligo and family 
and personal medical history were evaluated. Antinuclear auto-
antibodies, thyroid hormones and thyroid autoantibodies were 
measured. IgM-T3-Ab, IgG-T3-Ab, IgM-T4-Ab and IgG-T4-Ab 
were assayed by a radioimmunoprecipitation technique. Fisher’s 
test, c2-test and Student’s t-test were used for statistical analysis. 
The results showed a surprisingly high prevalence of THAbs in 
patients with vitiligo, prompting the authors to speculate that these 
antibodies may have a possible pathogenetic role in vitiligo. They 
conclude that further evaluation is now required in a larger group 
of patients. Br J Dermatol 2014; 171: 786–798.
Dermatoscopy, BRAF and NRAS mutations and 
melanoma
Pozzobon et al. start by explaining that the identification of BRAF 
mutations in melanoma has subsequently led to the development 
and implementation of new and effective therapies. However, 
few clinical and histological features have been associated with 
this mutational status. The authors’ main objective was to inves-
tigate clinical, histopathological and dermoscopic characteristics 
of primary melanomas according to BRAF or NRAS mutational 
status. This was an observational retrospective study including 
melanoma dermoscopy images assessed for somatic mutations 
in BRAF and NRAS. Seventy-two patients were included in the 
study. The authors reported that BRAF-mutated melanomas were 
more frequently located on the trunk (n = 18, 64% for BRAF-
mutated vs. n = 11, 29% for wild-type melanomas; P = 0.013). 
Histological ulceration was associated with the presence of BRAF 
mutations (odds ratio 3.141, 95% confidence interval 1.289–
7.655; P = 0.002). The Breslow index tended to be thicker in 
BRAF-mutated compared with wild-type melanomas (P = 0.086). 
BRAF mutations were present in 28 patients (39%), and only four 
cases (6%) were positive for NRAS mutations, with BRAF and 
NRAS mutations being mutually exclusive. They concluded that 
this study showed a correlation between BRAF and NRAS sta-
tus and dermoscopic findings of ‘peppering’ as an expression of 
regression and melanophages in the dermis, suggesting a mor-
phological consequence of immune behaviour in BRAF-mutated 
melanomas. Br J Dermatol 2014; 171: 754–759.
How to treat warts
The stated objective of this guideline is to provide up-to-date, evi-
dence-based recommendations for the management of infectious 
cutaneous warts caused by papillomavirus infection. The guide-
line provides an appraisal of all relevant literature since January 
1999, focusing on any key developments. It also addresses impor-
tant practical clinical questions relating to the accurate diagnosis 
and identification of cases and suitable treatment. Additionally, 
this guideline provides treatment recommendations and, where 
appropriate, considers their health economic implications. The 
guideline concludes by considering potential developments in 
this subject area and future directions for research. Br J Dermatol 
2014; 171: 696–712.
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